These findings, as well as our observation of an abnormal dose-response for ANG treatment in an ALS mouse model16,46, have implications for how ANG replacement therapy is administered and how clinical trials for ANG replacement are designed. This evidence concerns the gene ANG and amyotrophic lateral sclerosis.